Journals / Cukurova Medical Journal / 2014 / Cilt: 39 - Sayı: 1

The Discordance Between HER-2/NEU Expression Assessed by Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH): Is It Important to Detect?

HER-2/NEU Ekspresyonun Saptanmasinda İmmunohistokimyasal ve Fish Yöntemi Arasında Diskordansin Belirlenmesi Önemli midir?

Pages
53–60
Publication Date
2014-07-22
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As such, it would be beneficial for each hospital to determine its own discordance rate.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Assessment of HER-2 has become of great importance following the advent of HER-2 antibody treatment.
📊
Key Findings & Data:Use of trastuzumab therapy depends on the assessment of HER-2 via standard immunohistochemistry (IHC) assays for protein overexpression or via fluorescence in situ hybridization (FISH) for gene amplification.
💡
Conclusion & Impact:As such, it would be beneficial for each hospital to determine its own discordance rate.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Göğüs kanseri · HER-2/neu · IHC

Abstract

Purpose: Assessment of HER-2 has become of great importance following the advent of HER-2 antibody treatment. Use of trastuzumab therapy depends on the assessment of HER-2 via standard immunohistochemistry (IHC) assays for protein overexpression or via fluorescence in situ hybridization (FISH) for gene amplification. The aim of this study was to determine the rate of discordance between FISH and IHC in our hospital. The rate of discordance varies from hospital to hospital, and due to certain staff, technical, and biological reasons, IHC and FISH may not be concordant in every patient. It is important to determine the rate of discordance between these 2 methods and attempt to lower it. In addition to the rate of discordance, we also investigated the reasons for the discordance and what affect it has on the progression of the disease and treatment. Material and Methods: A total of 79 patients with breast cancer were assessed for HER-2 protein expression via IHC and HER-2 gene amplification via FISH. Results: Among these 79 patients, 47 (59.5%) were FISH (-) and 32 (40.5%) were FISH (+), whereas FISH was negative in 8 (10.4%) patients that were HER-2 (3+) and FISH was positive in 9 (11.4%) patients that were HER-2 (1+). The discordance rate was 21.5%. Conclusion: The clinical implication of this discordance rate and it's affect on the choice of appropriate therapy are of critical importance. As such, it would be beneficial for each hospital to determine its own discordance rate.

Özet

Amaç: HER-2"nin değerlendirilmesi, HER-2 antikor tedavisinin takibinde büyük öneme sahiptir. Transtuzumab tedavisinde HER-2"nin değerlendirilmesi protein aşırı üretiminin standart immünohistokimyasal yöntemler ile veya gen amplifikasyonunun FISH yöntemi ile belirlenmesine bağlıdır. Bu çalışmanın amacı hastanemizde kullanılan bu iki yöntem arasındaki diskordans oranını incelemektir. Diskordans oranı hastaneler arasında farklılık göstermektedir, bu farklılık çalışanlara, teknik nedenlere ve biyolojik nedenlere bağlı olabilmektedir. Dolayısıyla bu iki metod arasındaki diskordans oranını belirlemek ve bu oranı minimize önemlidir. Bunlara ek olarak, diskordansın sebeplerini, hastalığın ve tedavinin progresyonu üzerine nasıl etki ettiğini araştırdık. Materyal ve Metod: Meme kanseri tanısı alan toplam 79 hastada HER-2 protein ekspresyonu immunohistokimyasal, HER-2 gen amplifikasyonu ise FISH yöntemleriyle incelendi. Bulgular: İncelenen 79 hastadan 47 sinde (%59.5) FISH (-) 32 sinde (%40.5) FISH (+), öte yandan FISH negatif olan 8 (%10.4) hasta için HER-2 (3+) ve FISH pozitif 9 hasta (%11.4) içinde HER-2 (1+) bulundu. Diskordans oranı %21.5 tir. Sonuç: Diskordans oranının klinik implikasyonu uygun tedavi prosedürünü seçmek için önemlidir, bu yaklaşım hastanelerin kendi diskordans oranlarını belirlemeleri için faydalı olabilir.

🔖

Cite This Article

DUMAN, B. B., ŞAHİN, B., KARA, O. İ., ERKİŞİ, M., KIDIK, A., ERGİN, M., BAĞIR, E. K. (2014). The Discordance Between HER-2/NEU Expression Assessed by Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH): Is It Important to Detect?. Cukurova Medical Journal, Cilt: 39 - Sayı: 1, 53–60. https://ajindex.com/articles/57038

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987;235:177-82.
  2. Wollf AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Clin Oncol. 2007;25:118-45.
  3. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287. National Comprehensive Cancer Network (NCCN) Guidelines available online at www.nccn.org/professionals/physician_gls/f_guidelin es.asp (Accessed May 12, 2009).
  4. Sturgeon CM, Hoffman BR, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 2008;54: e1. Layfield LJ, Willmore-Payne C, Isom G, Holden JA. Monoplex LightCycler polymerase chain reaction quantitation of the HER2 gene for quality assurance of HER2/neu testing by immunohistochemistry and fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol. 2008;16:562-7.
  5. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-78.
  6. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the Her2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. Clin Oncol. 2000;18:3651 Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285-9.
  7. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2 overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-26.
  8. Yamauchi H, Stearns V, Hayes DF. When is a tumor ready for prime time? A case study o cerb B-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334-56.
  9. Konecny G, Pauletti G, Pegram M, et al. Quantative association between Her2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95:142-53.
  10. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the